Management of hepatic encephalopathy in patients with cirrhosis

Best Practice and Research in Clinical Gastroenterology

Volumn 21, Issue 1, 2007, Pages 95-110

  Wright, Gavin ^a   Jalan, Rajiv ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

acute on chronic liver failure; ammonia; astrocyte; cerebral oedema; systemic inflammatory response syndrome

Indexed keywords

ALBUMIN; AMMONIA; BENZOIC ACID; CEPHALOSPORIN; FLUMAZENIL; GLUTAMIC ACID; GLUTAMINE; HYDROCORTISONE; INDOMETACIN; INOTROPIC AGENT; LACTITOL; LACTULOSE; METRONIDAZOLE; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; NEOMYCIN; NORADRENALIN; NORFLOXACIN; ORNITHINE ASPARTATE; PLACEBO; PROBIOTIC AGENT; PROPOFOL; PROTEIN; RIFAXIMIN; SODIUM CHLORIDE; STEROID; SYNBIOTIC AGENT; TERLIPRESSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; ZINC;

ARTICLE; ASTROCYTE; BRAIN EDEMA; BRAIN HERNIA; CELL SWELLING; CLINICAL TRIAL; COMA; CONSCIOUSNESS LEVEL; DEATH; DIARRHEA; DIET RESTRICTION; DRUG DOSE REDUCTION; FLATULENCE; HEPATIC ENCEPHALOPATHY; HUMAN; INFLAMMATION; INTRACRANIAL HYPERTENSION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; MEMORY DISORDER; MENTAL CONCENTRATION; MENTAL DISEASE; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; OSMOSIS; OTOTOXICITY; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN RESTRICTION; PSYCHOMOTOR DISORDER; RESPONSE TIME; SENSORY DYSFUNCTION;

AMMONIA; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION;

EID: 33846168077     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2006.07.009     Document Type: Article

References (76)

1. Butterworth R.F., Giguere J.F., Michaud J., et al. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 6 (1987) 1-12
2. Haussinger D., Kircheis G., Fischer R., et al. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?. J Hepatol 32 (2000) 1035-1038
3. Cordoba J., Alonso J., Rovira A., et al. The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. J Hepatol 35 (2001) 598-604
4. Jalan R., Dabos K., Redhead D.N., et al. Elevation of intracranial pressure following transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. J Hepatol 27 (1997) 928-933
5. Gitlin N., Lewis D.C., and Hinkley L. The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis. J Hepatol 3 (1986) 75-82
6. Weissenborn K., Ennen J.C., Schomerus H., et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 34 (2001) 768-773
7. Ferenci P., Lockwood A., Mullen K., et al. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35 (2002) 716-721
8. Conn H.O. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 22 (1977) 541-550
9. Teasdale G., Knill-Jones R., and van der Sande J. Observer variability in assessing impaired consciousness and coma. J Neurol Neurosurg Psychiatry 41 (1978) 603-610
10. Bhatia V., Singh R., and Acharya S.K. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut 55 (2006) 98-104
11. Clemmesen J.O., Larsen F.S., Kondrup J., et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 29 (1999) 648-653
12. Master S., Gottstein J., and Blei A.T. Cerebral blood flow and the development of ammonia-induced brain edema in rats after portacaval anastomosis. Hepatology 30 (1999) 876-880
13. Olde Damink S.W., Jalan R., Deutz N.E., et al. The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. Hepatology 37 (2003) 1277-1285
14. Desjardins P., Rao K.V., Michalak A., et al. Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle. Metab Brain Dis 14 (1999) 273-280
15. Romero-Gomez M., Ramos-Guerrero R., Grande L., et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 41 (2004) 49-54
16. Blei A.T. Helicobacter pylori, harmful to the brain?. Gut 48 (2001) 590-591
17. Lockwood A.H., McDonald J.M., Reiman R.E., et al. The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clin Invest 63 (1979) 449-460
18. Restuccia T., Gomez-Anson B., Guevara M., et al. Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology 39 (2004) 1613-1622
19. Gabduzda G.J., and Hall III P.W. Relation of potassium depletion to renal ammonium metabolism and hepatic coma. Medicine (Baltimore) 45 (1966) 481-490
20. Hazell A.S., and Butterworth R.F. Hepatic encephalopathy: an update of pathophysiologic mechanisms. Proc Soc Exp Biol Med 222 (1999) 99-112
21. Rolando N., Harvey F., Brahm J., et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology 11 (1990) 49-53
22. Vaquero J., Polson J., Chung C., et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 125 (2003) 755-764
23. Muto Y., Nouri-Aria K.T., Meager A., et al. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 2 (1988) 72-74
24. Rolando N., Wade J., Davalos M., et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology 32 (2000) 734-739
25. Jalan R., Pollok A., Shah S.H., et al. Liver derived pro-inflammatory cytokines may be important in producing intracranial hypertension in acute liver failure. J Hepatol 37 (2002) 536-538
26. Aggarwal S., Obrist W., Yonas H., et al. Cerebral hemodynamic and metabolic profiles in fulminant hepatic failure: relationship to outcome. Liver Transpl 11 (2005) 1353-1360
27. Plauth M., Merli M., Kondrup J., et al. ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr 16 (1997) 43-55
28. Lochs H., and Plauth M. Liver cirrhosis: rationale and modalities for nutritional support - the European Society of Parenteral and Enteral Nutrition consensus and beyond. Curr Opin Clin Nutr Metab Care 2 (1999) 345-349
29. Marchesini G., Marzocchi R., Noia M., et al. Branched-chain amino acid supplementation in patients with liver diseases. J Nutr 135 (2005) 1596S-1601S
30. Als-Nielsen B., Koretz R.L., and Kjaergard L.L. Branched-chain amino acids for hepatic encephalopathy (Cochrane review). Cochrane Library (2004), John Wiley and Sons, Chichester, UK
31. Marchesini G., Bianchi G., Rossi B., et al. Nutritional treatment with branched-chain amino acids in advanced liver cirrhosis. J Gastroenterol 35 supplement 12 (2000) 7-12
32. Marchesini G., Fabbri A., Bianchi G., et al. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 23 (1996) 1084-1092
33. Agus Z.S., Dukes I.D., and Morad M. Divalent cations modulate the transient outward current in rat ventricular myocytes. Am J Physiol 261 (1991) C310-C318
34. Reding P., Duchateau J., and Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet 2 (1984) 493-495
35. Rose C., Butterworth R.F., Zayed J., et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 117 (1999) 640-644
36. Layrargues G.P., Rose C., Spahr L., et al. Role of manganese in the pathogenesis of portal-systemic encephalopathy. Metab Brain Dis 13 (1998) 311-317
37. Zieve L., Doizaki W.M., and Zieve J. Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 83 (1974) 16-28
38. Elmer G.W., and McFarland L.V. Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol Clin North Am 30 (2001) 837-854
39. Weissenborn K., Bokemeyer M., Ahl B., et al. Functional imaging of the brain in patients with liver cirrhosis. Metab Brain Dis 19 (2004) 269-280
40. Stokkeland K., Brandt L., Ekbom A., et al. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002. Hepatology 43 (2006) 500-505
41. Jalan R., Damink S.W., Deutz N.E., et al. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. Lancet 354 (1999) 1164-1168
42. Larsson A. Saline versus Albumin Fluid Evaluation (SAFE) study. Albumin does not increase the mortality of intensive care patients. A study with many aspects. Ugeskr Laeger 166 (2004) 3836-3837
43. Harry R., Auzinger G., and Wendon J. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 36 (2002) 395-402
44. Shawcross D.L., Davies N.A., Mookerjee R.P., et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology 39 (2004) 471-475
45. Jalan R., Olde Damink S.W., Deutz N.E., et al. Restoration of cerebral blood flow autoregulation and reactivity to carbon dioxide in acute liver failure by moderate hypothermia. Hepatology 34 (2001) 50-54
46. Als-Nielsen B., Gluud L.L., and Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 328 (2004) 1046
47. Conn H.O., Leevy C.M., Vlahcevic Z.R., et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 72 (1977) 573-583
48. Strauss E., Tramote R., Silva E.P., et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 39 (1992) 542-545
49. Blanc P., Daures J.P., Liautard J., et al. Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial. Gastroenterol Clin Biol 18 (1994) 1063-1068
50. Williams R., James O.F., Warnes T.W., et al. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 12 (2000) 203-208
51. Tarao K., Ikeda T., Hayashi K., et al. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 31 (1990) 702-706
52. Bucci L., and Palmieri G.C. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 13 (1993) 109-118
53. Sushma S., Dasarathy S., Tandon R.K., et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 16 (1992) 138-144
54. Efrati C., Masini A., Merli M., et al. Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution. Am J Gastroenterol 95 (2000) 3574-3578
55. Kircheis G., Nilius R., Held C., et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 25 (1997) 1351-1360
56. Rose C., Michalak A., Rao K.V., et al. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 30 (1999) 636-640
57. Jalan R., and Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci (Lond) 106 (2004) 467-474
58. Cordoba J., Lopez-Hellin J., Planas M., et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 41 (2004) 38-43
59. Langouche L., Vanhorebeek I., Vlasselaers D., et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 115 (2005) 2277-2286
60. Houstis N., Rosen E.D., and Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440 (2006) 944-948
61. Mechtcheriakov S., Graziadei I.W., Mattedi M., et al. Incomplete improvement of visuo-motor deficits in patients with minimal hepatic encephalopathy after liver transplantation. Liver Transpl 10 (2004) 77-83
62. Uribe M., Campollo O., Vargas F., et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 7 (1987) 639-643
63. Murphy N., Auzinger G., Bernel W., et al. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 39 (2004) 464-470
64. Fernandez J., Monteagudo J., Bargallo X., et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 42 (2005) 627-634
65. Sort P., Navasa M., Arroyo V., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341 (1999) 403-409
66. Sanyal A.J., Genning C., Reddy K.R., et al. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 124 (2003) 634-641
67. Bernard B., Grange J.D., Khac E.N., et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 29 (1999) 1655-1661
68. Riggio O., Masini A., Efrati C., et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 42 (2005) 674-679
69. Goulenok C., Bernard B., Cadranel J.F., et al. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther 16 (2002) 361-372
70. Macbeth W.A., Kass E.H., and McDermott Jr. W.V. Treatment of hepatic encephalopathy by alteration of intestinal flora with Lactobacillus acidophilus. Lancet 191 (1965) 399-403
71. Read A.E., McCarthy C.F., Heaton K.W., et al. Lactobacillus acidophilus (enpac) in treatment of hepatic encephalopathy. BMJ 5498 (1966) 1267-1269
72. Loguercio C., Del Vecchio Blanco C., and Coltorti M. Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. J Int Med Res 15 (1987) 335-343
73. Loguercio C., Abbiati R., Rinaldi M., et al. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 23 (1995) 39-46
74. Liu Q., Duan Z.P., Ha da K., et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39 (2004) 1441-1449
75. Solga S.F. Probiotics can treat hepatic encephalopathy. Med Hypotheses 61 (2003) 307-313
76. Bongaerts G., Severijnen R., and Timmerman H. Effect of antibiotics, prebiotics and probiotics in treatment for hepatic encephalopathy. Med Hypotheses 64 (2005) 64-68